China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) was the recipient of a significant increase in short interest in October. As of October 15th, there was short interest totaling 721,044 shares, an increase of 999.1% from the September 30th total of 65,603 shares. Based on an average daily volume of 52,120,891 shares, the short-interest ratio is currently 0.0 days. Approximately 157.1% of the company’s stock are short sold.
China SXT Pharmaceuticals Stock Up 3.0%
Shares of NASDAQ:SXTC opened at $3.65 on Wednesday. The company has a 50-day moving average price of $202.02 and a 200-day moving average price of $25,799.88. China SXT Pharmaceuticals has a 12 month low of $3.28 and a 12 month high of $8,375,880.00.
Wall Street Analyst Weigh In
SXTC has been the topic of several recent analyst reports. Weiss Ratings upgraded shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Wednesday, October 21st. Wall Street Zen upgraded shares of China SXT Pharmaceuticals to a “sell” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, China SXT Pharmaceuticals has an average rating of “Sell”.
Check Out Our Latest Research Report on SXTC
About China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc (NASDAQ: SXTC) is a pharmaceutical company based in Taizhou, Jiangsu Province, China. The company develops, manufactures and sells traditional Chinese medicine products, serving customers primarily in the Chinese market.
Its product portfolio includes prescription and over-the-counter traditional Chinese medicines, as well as health-related products and dietary supplements. The company’s operations encompass the preparation of herbal ingredients and the production, marketing and distribution of finished traditional Chinese medicine products.
China SXT Pharmaceuticals was established in 2005 and completed its initial public offering on the Nasdaq Capital Market in 2019.
Featured Stories
- Five stocks we like better than China SXT Pharmaceuticals
- 3 Growth Stocks Under $20 With Hard Catalyst Dates Ahead
- Is United Parcel Service Finally Turning the Corner?
- Taiwan Semiconductor Flexes Pricing Power on AI’s Frontline
- Hidden in Plain Sight: 2 Earnings Winners Investors May Have Missed
Receive News & Ratings for China SXT Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China SXT Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
